"Blocking the mechanism that cancer cells exploit to avoid destruction by the immune system could spur new treatments for the disease. Researchers have developed an antibody that prevents pancreatic cancer cells from evading the immune system and slows tumour growth. The discovery could lead to more treatment options for pancreatic ductal adenocarcinoma - the most common type of pancreatic cancer, which has limited treatment options and a low survival rate."
"Blocking the mechanism that cancer cells exploit to avoid destruction by the immune system could spur new treatments for the disease."
An antibody has been developed that prevents pancreatic cancer cells from evading the immune system and slows tumour growth. The antibody blocks the mechanism that cancer cells exploit to avoid destruction by immune cells. Slowing tumour growth indicates restored immune-mediated tumour control in experimental settings. The approach targets pancreatic ductal adenocarcinoma, the most common pancreatic cancer subtype, which has limited treatment options and low survival rates. The finding provides a potential foundation for new therapies aimed at reversing immune evasion in aggressive pancreatic tumours.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]